Drug Trial Radar · NCT06564246
Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Sep 18, 2024
Primary completion
Aug 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Tanta UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 17 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
Vonoprazan 20 mg versus Pantoprazole 40 mgDrug
Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in the measured biomarkerTime frame: Before and after 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Theodore Billiharz Institute for Researchs
Giza, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.